Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search


MiRXES is a Singapore-based biotechnology company specializing in microRNA-based diagnostics founded in 2014.

MiRXES is a Singapore-headquartered biotech firm with R&D, manufacturing, and clinical lab operations in Singapore, USA, Japan, and China. A molecular diagnostics company, it specializes in microRNA technologies and the development, manufacturing, and provision of diagnostic test kits and clinical services.

MiRXES offers blood tests which use microRNAs - small strands of genetic code found in the bloodstream - as cancer markers. Blood-based microRNAs have, within their genetic code, information about the cancer profiles they carry and therefore have potential to work as a signaler for the presence of different types of cancer.

In February 2020, MiRXES won the rights to manufacture and commercialize the Sars-CoV-2 diagnostic test kits for the novel coronavirus COVID-19. The diagnostic test kit was developed by Singapore's Agency for Science, Technology and Research (A*Star) and Tan Tock Seng Hospital, and has received provisional authorization from the Health Sciences Authority.MiRXES is backed by Singapore-based venture capital firm Venturecraft, which invests in global growth-stage and late-stage ventures in medtech, biotech, and digital health.


March 3, 2020
Singapore Clears New SARS-CoV-2 Assay for Clinical Use

Singapore's Health Sciences Authority gave the MiRXES's testing kits provisional approval for use in clinical settings.

MiRXES is the manufacturer of the test, which was developed in collaboration between the Agency for Science, Technology and Research (A*Star) and Tan Tock Seng Hospital.

The test, called A*STAR Fortitude 2.0, is a real-time PCR assay. Results are generated using a nasopharyngeal swab collected from patients. The product supports the analysis of up to 188 samples per kit.

As of early March 2020, MiRXES has manufactured 100,000 tests in the past few weeks and has shipped around 20,000 tests to local and regional hospitals.

MiRXES has a non-exclusive license to produce the test.

February 18, 2020
MiRXES commits to mass production of its SARS-CoV-2 diagnostic test kits

The PCR test was developed in three weeks in collaboration between the Agency for Science, Technology and Research (A*Star) and Tan Tock Seng Hospital, and received approval from the Health Sciences Authority.

The initial batch was manufactured by the Diagnostics Development (DxD) Hub, which also supported the verification of the tests. However, the DxD Hub is now handing the baton off to MiRXES

March 14, 2014
MiRXES was founded by Lihan Zhao and Zou Ruiyang.

Funding Rounds


Further Resources



Golden logo
By using this site, you agree to our Terms & Conditions.